Last reviewed 2026-05-14 · How we verify

Gynodian® Depot (BAY86-5032)

Bayer · Phase 3 active Small molecule

Gynodian® Depot (BAY86-5032) is a GnRH agonist Small molecule drug developed by Bayer. It is currently in Phase 3 development for Endometriosis, Uterine fibroids (leiomyomas).

Gynodian Depot is a long-acting gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone to reduce estrogen levels.

Gynodian Depot is a long-acting gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone to reduce estrogen levels. Used for Endometriosis, Uterine fibroids (leiomyomas).

At a glance

Generic name	Gynodian® Depot (BAY86-5032)
Sponsor	Bayer
Drug class	GnRH agonist
Target	GnRH receptor
Modality	Small molecule
Therapeutic area	Endocrinology / Gynecology
Phase	Phase 3

Mechanism of action

BAY86-5032 is a depot formulation designed for extended-release delivery of a GnRH agonist, which works by initially stimulating then desensitizing GnRH receptors on pituitary gonadotroph cells. This leads to sustained suppression of gonadal sex hormone production, creating a hypogonadal state useful in hormone-dependent conditions. The depot formulation allows for less frequent dosing compared to shorter-acting GnRH agonists.

Approved indications

Endometriosis
Uterine fibroids (leiomyomas)

Common side effects

Hot flashes
Vaginal dryness
Headache
Mood changes / depression
Decreased bone mineral density

Key clinical trials

Efficacy of Gynodian® Depot in Women With Impaired Well-being (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gynodian® Depot (BAY86-5032) CI brief — competitive landscape report
Gynodian® Depot (BAY86-5032) updates RSS · CI watch RSS
Bayer portfolio CI

Frequently asked questions about Gynodian® Depot (BAY86-5032)

What is Gynodian® Depot (BAY86-5032)?

Gynodian® Depot (BAY86-5032) is a GnRH agonist drug developed by Bayer, indicated for Endometriosis, Uterine fibroids (leiomyomas).

How does Gynodian® Depot (BAY86-5032) work?

Gynodian Depot is a long-acting gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone to reduce estrogen levels.

What is Gynodian® Depot (BAY86-5032) used for?

Gynodian® Depot (BAY86-5032) is indicated for Endometriosis, Uterine fibroids (leiomyomas).

Who makes Gynodian® Depot (BAY86-5032)?

Gynodian® Depot (BAY86-5032) is developed by Bayer (see full Bayer pipeline at /company/bayer).

What drug class is Gynodian® Depot (BAY86-5032) in?

Gynodian® Depot (BAY86-5032) belongs to the GnRH agonist class. See all GnRH agonist drugs at /class/gnrh-agonist.

What development phase is Gynodian® Depot (BAY86-5032) in?

Gynodian® Depot (BAY86-5032) is in Phase 3.

What are the side effects of Gynodian® Depot (BAY86-5032)?

Common side effects of Gynodian® Depot (BAY86-5032) include Hot flashes, Vaginal dryness, Headache, Mood changes / depression, Decreased bone mineral density.

What does Gynodian® Depot (BAY86-5032) target?

Gynodian® Depot (BAY86-5032) targets GnRH receptor and is a GnRH agonist.

Drug class: All GnRH agonist drugs
Target: All drugs targeting GnRH receptor
Manufacturer: Bayer — full pipeline
Therapeutic area: All drugs in Endocrinology / Gynecology
Indication: Drugs for Endometriosis
Indication: Drugs for Uterine fibroids (leiomyomas)
Compare: Gynodian® Depot (BAY86-5032) vs similar drugs
Pricing: Gynodian® Depot (BAY86-5032) cost, discount & access